Systematic review of 21 studies (10 RCTs, 11 cohorts) of women on anticoagulation for VTE: overall uterine bleeding risk did not differ for DOACs vs LMWH/VKA (RR 1.47; 0.93–2.33), but unspecified abnormal uterine bleeding was higher (RR 2.68), notably with rivaroxaban.
Meta-analysisn = 21 studies
Taree et al. Rate of abnormal uterine bleeding in women on anticoagulation for venous thromboembolism: systematic review and meta-analysis